Celeste Lebbé, MD, PhD
Institut National de la Santé Et de la Recherche Médicale, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Celeste Lebbé, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01412515 · A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's SarcomaInstitut National de la Santé Et de la Recherche Médicale, France · terminated · Kaposi Sarcoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.